Business
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines.
About this update from Eli Lilly And Company
[{"type":"text","content":"INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines.","length":361,"tagName":"p"},{"type":"text","content":"Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer and head of development at Denali Therapeutics, where she built and led the company's translational medicine and clinical development strategy.","length":492,"tagName":"p"},{"type":"text","content":"Adrienne Brown, currently group vice president of corporate business development at Lilly, has been promoted to executive vice president and president, Lilly Immunology, and will join the Executive Committee. Throughout her more than 20 years at Lilly, Brown has held leadership positions with expanding responsibilities across U.S. and Japan operations, business development, sales, marketing and commercial strategy, including leading the U.S. launch of Mounjaro.","length":465,"tagName":"p"},{"type":"text","content":"Daniel Skovronsky, M.D., Ph.D., will assume an expanded role as chief scientific and product officer, and president, Lilly Research Laboratories, overseeing research and development as well as global launches and product strategy for Cardiometabolic Health, Immunology and Neuroscience. He will continue to report directly to David A. Ricks, Lilly chair and CEO, and remain on the Executive Committee. New Executive Committee members Ho and Brown and continuing Executive Committee member Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health, will report to Skovronsky.","length":608,"tagName":"p"},{"type":"text","content":"Jacob Van Naarden, executive vice president and president, Lilly Oncology, will also assume an expanded role with the corporate business development function moving under his leadership. Van Naarden will continue to repo...